PTN Overview
Upcoming Projects (PTN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (PTN)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (PTN)
-
An expert’s view on Vyleesi (Bremelanotide) in Female sexual dysfunction after the FDA's approval
Tickers: PTN, AMAG
Execute By: Jul 05, 2019
Upcoming & Overdue Catalysts (PTN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (PTN)
-
Assuming the Phase 3 trials are successful, Palatin will file a New Drug Application for Bremelanotide in early 2018
Ticker: PTN
Occurred on: Mar 26, 2018 -
Top Line data of 2 Phase 3 trials for Bremelanotide in female sexual dysfunction (FSD)
Tickers: PTN, VRX
Occurred on: Nov 01, 2016 -
FDA Issues Guidance Clarifying the Requirements for Developers of Female Sexual Desire Drugs
Tickers: PTN, VRX
Occurred on: Oct 25, 2016 -
Palatin Technologies Presents Bremelanotide initial data from Phase 3 trials for HSDD
Ticker: PTN
Occurred on: Sep 23, 2016 -
Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction
Ticker: PTN
Occurred on: Feb 08, 2016
Strategic Initiatives (PTN)
-
Vyleesi approval in U.S. triggers a $60 million milestone payment to Palatin(PTN) under its North American license agreement with AMAG
Ticker: PTN
Announcement Date: Jun 21, 2019
